Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab.

Luca Quartuccio Ginevra De MarchiRossana DomenisNicola CabasSilvia GuellaAntonella ParadisoCinzia FabroAntonio Paolo BeltramiSalvatore De VitaFrancesco Curcio

Published in: Journal of clinical medicine (2023)

The third dose of mRNA COVID-19 vaccine can restore both humoral and cellular immune response in SLE patients on Belimumab.

Keyphrases

immune response
systemic lupus erythematosus
end stage renal disease
ejection fraction
sars cov
coronavirus disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
binding protein
rheumatoid arthritis
inflammatory response